Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G(D2) immunotherapy and isotretinoin: a prospective Phase II study

Relapse of high-risk neuroblastoma (HR-NB) is deemed invariably fatal yet increasing numbers of HR-NB patients achieve a second complete/very good partial remission (CR/VGPR), hence the urgency to find a successful consolidative therapy. Identifying efficacy in patients without assessable disease, h...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Autores principales: Kushner, Brian H, Ostrovnaya, Irina, Cheung, Irene Y, Kuk, Deborah, Kramer, Kim, Modak, Shakeel, Yataghene, Karima, Cheung, Nai-Kong V
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2015
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485744/
https://ncbi.nlm.nih.gov/pubmed/26140243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1016704
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares